Treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients. A prospective randomized multicenter international study with Denosumab Vs Alendronate
Articolo
Data di Pubblicazione:
2017
Citazione:
Treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients. A prospective randomized multicenter international study with Denosumab Vs Alendronate / Doria, Carlo; Mosele, Giulia R; Solla, Federico; Maestretti, Gianluca; Balsano, Massimo; Scarpa, Roberto M.. - In: MINERVA UROLOGICA E NEFROLOGICA. - ISSN 0393-2249. - 69:3(2017), pp. 271-277.
Abstract:
Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. This is a multicenter, randomized, double-blind prospective study on use of Denosumab versus Alendronate in the therapy of secondary osteoporosis related to ADT.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Doria, Carlo; Mosele, Giulia R; Solla, Federico; Maestretti, Gianluca; Balsano, Massimo; Scarpa, Roberto M.
Link alla scheda completa:
Pubblicato in: